Pharmaceutical Engineering Center, Chongqing Medical and Pharmaceutical College, Chongqing, China.
Chemistry and Chemical Engineering College, Huangshan University, Huangshan, China.
J Drug Target. 2022 Mar;30(3):259-268. doi: 10.1080/1061186X.2021.1973482. Epub 2021 Sep 3.
Alzheimer's disease (AD), which is recognised as a devastating neurodegenerative disease throughout the world and lack of effective treatments, is a growing concern in modern society with a growing population of elderly patients. A growing number of studies reveal that abnormal accumulation and deposition of Aβ is responsible for AD. Inspired by this, strategies for the treatment of AD targeting-Aβ clearance have been discussed for a long period, exploring new drugs which is capable of destroying soluble Aβ oligomers and unsolvable Aβ aggregates. In this paper, results of recent clinical trials on several anti-amyloid-β drugs are presented and several emerging anti-amyloid AD therapies based on recent studies are reviewed. Furthermore, some of the current challenges and novel strategies to prevent AD are addressed. Herein, this review focuses on current pharmacotherapy of AD targeting-Aβ and intends to design a promising therapeutic agent for AD treatment.
阿尔茨海默病(AD)是一种全球公认的破坏性神经退行性疾病,目前尚无有效的治疗方法,随着老年患者人数的不断增加,这一问题在现代社会中日益受到关注。越来越多的研究表明,Aβ 的异常积累和沉积是 AD 的罪魁祸首。受此启发,针对 Aβ 清除的 AD 治疗策略已经讨论了很长一段时间,探索能够破坏可溶性 Aβ 低聚物和不可溶 Aβ 聚集体的新药。本文介绍了几种抗淀粉样蛋白-β药物的最新临床试验结果,并综述了基于最近研究的几种新兴抗淀粉样蛋白 AD 治疗方法。此外,还讨论了目前预防 AD 的一些挑战和新策略。本文重点介绍了针对 Aβ 的 AD 现行药物疗法,并旨在为 AD 治疗设计一种有前途的治疗剂。